Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib for recurrent epithelial ovarian cancer
ChiCTR2300070839Phase 4Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in epithelial ovarian cancer (EOC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: objective response rate. Started Feb 2021; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ChiCTR2300070839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070839.